DIFFERENTIAL-EFFECTS OF 3 DOPAMINE-RECEPTOR AGONISTS IN MPTP-TREATED MONKEYS

被引：29

作者：

ARAI, N

ISAJI, M

MIYATA, H

FUKUYAMA, J

MIZUTA, E

KUNO, S

机构：

[1] NATL UTANO HOSP,DEPT NEUROL,KYOTO 616,JAPAN

[2] NATL UTANO HOSP,CLIN RES CTR,KYOTO 616,JAPAN

[3] KISSEI PHARMACEUT CO LTD,PHARMACOL LAB,NAGANO,JAPAN

来源：

JOURNAL OF NEURAL TRANSMISSION-PARKINSONS DISEASE AND DEMENTIA SECTION | 1995年 / 10卷 / 01期

关键词：

DOPAMINE RECEPTOR AGONISTS; PARKINSONS DISEASE; PARKINSONISM; HYPERACTIVITY;

D O I：

10.1007/BF02256629

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The behavioral effects of cabergoline, pergolide and bromocriptine were investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys with attention to the induction of hyperactivity, as evidenced by irritability, excitability and aggressiveness. All three drugs improved the parkinsonism in a dose-dependent fashion following a single injection. Among the three dopamine (DA) receptor agonists used, the antiparkinsonian effect of pergolide was the strongest and had an immediate effect, while cabergoline showed the longest duration of the antiparkinsonian effect and was least potent in inducing hyperactivity.

引用

页码：55 / 62

页数：8

共 10 条

[1] BEHAVIORAL INVOLVEMENT OF CENTRAL DOPAMINE D-1 AND D-2 RECEPTORS IN 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE(MPTP)-LESIONED PARKINSONIAN CYNOMOLGUS MONKEYS
AKAI, T
OZAWA, M
YAMAGUCHI, M
MIZUTA, E
KUNO, S
[J]. JAPANESE JOURNAL OF PHARMACOLOGY, 1995, 67 (02) : 117 - 124
[2] A PRIMATE MODEL OF PARKINSONISM - SELECTIVE DESTRUCTION OF DOPAMINERGIC-NEURONS IN THE PARS COMPACTA OF THE SUBSTANTIA NIGRA BY N-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE
BURNS, RS
CHIUEH, CC
MARKEY, SP
EBERT, MH
JACOBOWITZ, DM
KOPIN, IJ
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (14): : 4546 - 4550
[3] CALNE DB, 1993, NEW ENGL J MED, V329, P1021
[4] LEVODOPA-INDUCED DYSKINESIA AND RESPONSE FLUCTUATIONS IN PRIMATES RENDERED PARKINSONIAN WITH 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP)
CLARKE, CE
SAMBROOK, MA
MITCHELL, IJ
CROSSMAN, AR
[J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1987, 78 (03) : 273 - 280
[5] CLEMENS JA, 1993, ARZNEIMITTEL-FORSCH, V43-1, P281
[6] LONG-LASTING PROLACTIN-LOWERING EFFECT OF CABERGOLINE, A NEW DOPAMINE AGONIST, IN HYPERPROLACTINEMIC PATIENTS
FERRARI, C
BARBIERI, C
CALDARA, R
MUCCI, M
CODECASA, F
PARACCHI, A
ROMANO, C
BOGHEN, M
DUBINI, A
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 63 (04) : 941 - 945
[7] PSYCHIATRIC SIDE EFFECTS OF LEVODOPA IN MAN
GOODWIN, FK
[J]. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1971, 218 (13) : 1915 - +
[8] CABERGOLINE IN PARKINSONS-DISEASE - LONG-TERM FOLLOW-UP
LERA, G
VAAMONDE, J
RODRIGUEZ, M
OBESO, JA
[J]. NEUROLOGY, 1993, 43 (12) : 2587 - 2590
[9] ON-OFF EFFECTS IN PATIENTS WITH PARKINSONS-DISEASE ON CHRONIC LEVODOPA THERAPY
MARSDEN, CD
PARKES, JD
[J]. LANCET, 1976, 1 (7954) : 292 - 296
[10] STEIGER MJ, 1992, HDB PARKINSONS DIS, P391

← 1 →